ZARVY

HCQS 400 is a high-strength medication containing Hydroxychloroquine 400mg, manufactured by IPCA Laboratories Ltd. It is commonly prescribed for managing autoimmune disorders such as rheumatoid arthritis and lupus erythematosus. Additionally, HCQS 400 is effective in the prevention and treatment of malaria caused by specific Plasmodium species. This medication works by modulating the immune response and disrupting the life cycle of malaria parasites. - COVID-19 management: Although studied for its potential in treating COVID-19, its efficacy remains controversial and is not widely endorsed by health authorities.

OXCQ 400 is a generic medication manufactured by Wallace Pharmaceuticals Pvt Ltd, containing hydroxychloroquine (400mg) as its active ingredient. Known for its effectiveness, this medication is widely utilized in the treatment and prevention of malaria, as well as in the management of autoimmune conditions such as lupus and rheumatoid arthritis. Hydroxychloroquine works by disrupting the lifecycle of malaria parasites in red blood cells, ensuring effective control and prevention of infection. For autoimmune diseases, it acts as an immunomodulator, reducing inflammation and alleviating symptoms caused by an overactive immune response. Additionally, OXCQ 400 has been investigated for its potential off-label use in managing COVID-19 symptoms. While its use for this purpose is not universally approved, research has highlighted its anti-inflammatory and antiviral properties, which may help in reducing respiratory inflammation and mitigating severe symptoms during infection.

ZY-Q 400 is a generic medication manufactured by Cadila Healthcare Ltd (Zydus), containing hydroxychloroquine (400mg) as its active ingredient. This versatile medication is widely recognized for its effectiveness in treating and preventing malaria and its role in managing autoimmune conditions such as lupus and rheumatoid arthritis. Hydroxychloroquine operates by increasing the pH within infected cells, which disrupts the lifecycle of malaria parasites, ensuring efficient prevention and control of the infection. Additionally, it functions as an immunomodulator, reducing excessive immune responses and inflammation in autoimmune diseases. Recently, ZY-Q 400 has garnered attention for its off-label use in COVID-19 management. Studies have explored its anti-inflammatory and antiviral properties, which may help alleviate severe respiratory symptoms and inflammation associated with the virus, though its use for this purpose remains under clinical investigation and varies by region.

HQTOR 400 is a generic medication manufactured by Torrent Pharmaceuticals Ltd, containing hydroxychloroquine (400mg) as its active ingredient. This versatile drug is widely used for malaria prevention and treatment, autoimmune disease management, and as an off-label option for COVID-19-related symptoms. Hydroxychloroquine is renowned for its ability to disrupt the lifecycle of malaria parasites in red blood cells, preventing the spread of infection. Its immunomodulatory properties also make it a trusted choice for controlling inflammation in lupus and rheumatoid arthritis. In recent years, HQTOR 400 has gained attention for its potential off-label use in treating COVID-19. Its anti-inflammatory and antiviral effects have been explored as a means to alleviate respiratory symptoms and reduce inflammation associated with the virus, although its use for this purpose remains under clinical evaluation and varies by region.

HETQ 400 is a generic medication manufactured by Hetero Healthcare Pvt Ltd, containing hydroxychloroquine (400mg) as its active ingredient. Known for its broad applications, this medication is essential in the prevention and treatment of malaria and in managing autoimmune conditions like lupus and rheumatoid arthritis. Hydroxychloroquine, the active compound in HETQ 400, interferes with the lifecycle of malaria parasites within red blood cells, effectively halting their replication. Beyond its antimalarial properties, it plays a significant role in autoimmune therapy by modulating immune responses to reduce inflammation and prevent tissue damage. HETQ 400 has also been examined for its off-label use in managing COVID-19. Although its use in this context varies globally and remains under clinical review, studies have explored its potential in alleviating severe respiratory symptoms and controlling inflammatory responses associated with the virus.